GenMark Prices 7M Shares Offering; Stock Soars | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics has priced its public offering of nearly 7.1 million shares of common stock at $4.25 per share.

The Carlsbad, Calif.-based molecular diagnostics firm said that it expects net proceeds from the offering to be roughly $27.6 million. If the underwriters exercise the over-allotment option of nearly 1.1 million shares, the firm's net proceeds will be approximately $31.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.